Skip to main content
SpringerLink
Log in

Nusinersen with screening for spinal muscular atrophy cost effective?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

Reference

  • Jalali A, et al. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy. Journal of Pediatrics : 10 Jul 2020. Available from: URL: http://doi.org/10.1016/j.jpeds.2020.07.033

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nusinersen with screening for spinal muscular atrophy cost effective?. PharmacoEcon Outcomes News 858, 25 (2020). https://doi.org/10.1007/s40274-020-6998-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6998-8

Search

Navigation